OmniAb, Inc.
Rachel Armstrong has a diverse background in talent acquisition and recruitment. Their most recent role is as a Talent Acquisition Manager at OmniAb, Inc. starting in May 2023. Prior to that, they worked as a Talent Partner, Technical at Freenome from January 2022 to April 2023. From October 2019 to January 2022, Rachel served as a Senior Talent Acquisition Specialist, Technical at Apeel. Rachel also gained experience at Expanxion, where they held the titles of Senior Technical Recruiter from August 2018 to October 2019 and Technical Recruiter from March 2018 to August 2018. At Expanxion, Rachel successfully developed and maintained business partnerships, consistently achieved hiring goals, and mentored new team members.
Rachel Armstrong holds a Bachelor's degree in Business, with a focus on Accounting and Business/Management, from California State University Channel Islands. Rachel has also obtained additional certifications, including "Leverage Diversity and Inclusion for Organizational Excellence" from Stanford University Graduate School of Business and "Talent Advisor" from ERE.
This person is not in any offices
OmniAb, Inc.
The OmniAb discovery platform provides pharmaceutical industry partners with access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics. At the heart of the OmniAb platform is the Biological Intelligence (BI) of our proprietary transgenic animals, including OmniRat,OmniChicken and OmniMouse, which have been genetically modified to generate antibodies with human sequences to facilitate development of human therapeutic candidates. OmniFlic (transgenic rat) and OmniClic (transgenic chicken) address industry needs for bispecific antibody applications though a common light chain approach, and OmniTaur features unique structural attributes of cow antibodies for complex targets. OmniAb animals comprise the most diverse host systems available in the industry and they are optimally leveraged through computational antigen design and immunization methods, paired with high-throughput microfluidic-based single B cell screening and deep computational analysis of next-generation sequencing datasets to identify fully human antibodies with superior performance and developability characteristics. An established core competency focused on ion channels and transporters further differentiates our technology and creates opportunities to further leverage across modalities, including antibody-drug conjugates and others. The OmniAb suite of technologies and differentiating computational capabilities and BI features are combined to offer a highly efficient and customizable end-to-end solution for the growing discovery needs of the global pharmaceutical industry. For more information, please visit www.omniab.com.